| Oct 11 |
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
|
| Oct 10 |
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
|
| Oct 9 |
MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges
|
| Oct 4 |
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up
|
| Sep 24 |
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
|
| Sep 17 |
MaxCyte and Kamau Therapeutics sign platform license agreement
|
| Sep 16 |
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
|
| Sep 5 |
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
|
| Aug 21 |
MaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five years
|
| Aug 7 |
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
|
